Abstract

Background. Coronavirus disease 2019 (COVID-19) is a serious worldwide threat presented by a broad range of symptoms, from mild flu to severe pneumonia. A rising number of atypical infections have been reported. Thus, scientists and clinicians are doing hard work to unravel scientific knowledge about this novel pandemic.

Objectives. The aim of the present work was to highlight the oral manifestations which could be observed in mild-to-moderate cases of COVID-19.

Material and methods. A questionnaire survey was performed on 665 Egyptian patients who were confirmed COVID-19-positive based on the polymerase chain reaction (PCR) test. After applying the exclusion criteria, cases with mild-to-moderate symptoms were included in the study. The questionnaire consisted of 4 sections. The 1st section included demographic data, smoking, alcohol consumption, and general health status. The 2nd section contained questions regarding the oral hygiene status of the patients, and additionally a question about the hygienic measures they took while being infected with COVID-19. The 3rd section included questions about the most commonly reported COVID-19 symptoms the patients suffered from. The 4th section included questions that referred to the oral manifestations the patients complained of while being infected with COVID-19.

Results. A total of 573 patients were included in this survey. It was reported that 71.7% of COVID-19 patients presented with some oral manifestations at a level of significance, with variable incidence — oral or dental pain (23%), pain in jaw bones or joint (12.0%), halitosis (10.5%), ulcerations (20.4%), and xerostomia (47.6%). Some patients (28.3%) showed 2 or 3 manifestations simultaneously.

Conclusions. It was proven that mild-to-moderate cases of COVID-19 infection are associated with oral symptoms, and thus the significance of dental examination of patients with communicable diseases should be emphasized.

Key words: xerostomia, oral hygiene, halitosis, coronavirus, COVID-19
Introduction

Coronavirus disease 2019 (COVID-19) is a serious worldwide threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In COVID-19, initially lungs are infected, and patients can present with a broad range of symptoms, from mild flu to severe pneumonia and possibly fatal respiratory illness. In COVID-19 infection, the most commonly reported symptoms are a headache, a sore throat, diarrhea, the loss of taste and smell, and shortness of breath. Dermatological manifestations have also been observed, and few authors have reported oral signs and symptoms. It is not strange that COVID-19 can manifest itself through oral symptoms, since various pulmonary diseases and systemic disorders with pulmonary involvement are associated with oral manifestations.

Meticulous checkups of the oral cavity in respiratory medicine can help in clinical diagnosis, and in providing advice and guidance to patients. In addition, dentists who detect atypical oral lesions should seek appropriate guidance and professional medical advice.

Objectives

The main objective of this study was to highlight the oral manifestations which could be reported in mild-to-moderate cases of COVID-19. Moreover, our goal was to spread awareness among physicians, general and dental practitioners, about these oral symptoms so that early diagnosis could be achieved, thus maintaining patient’s ultimate health and welfare.

Subjects and methods

Study design

An online questionnaire was designed for this investigation, because nearly all available questionnaires did not address the various possible oral manifestations of COVID-19 infection. A total of 665 Egyptian patients who recovered from COVID-19 were recruited from several Ministry of Health and university hospitals, including recovered dentists, nurses and physicians, who voluntarily participated in answering the questionnaire. A sharable link on Google Drive was sent to each patient via a WhatsApp message. A digital consent to participate in this study was obtained before completing the questionnaire. A web-based survey tool (Google Forms) was used to design the questionnaire.

Assessment of the oral hygiene status

The oral hygiene of the patients was measured based on their answers from the 2nd section of the questionnaire, where the best answer for each question was given score ‘1’, while ‘0’ was given to other choices. The full score was 12; the participant’s oral hygiene was considered good when at least 75% of this score was obtained.
Table 1. Questionnaire for investigating the oral manifestations of coronavirus disease 19 (COVID-19)

| Questions                                      | Answers                    |
|------------------------------------------------|----------------------------|
| Do you agree to participate in this study?     | yes                        |
|                                               | no                         |
| **1st section: Demographic data**              |                            |
| Gender                                         | male                       |
| Age                                            | female                     |
| Nationality                                    | Egyptian                   |
| Level of education                             | other                      |
| Chronic illnesses                              | yes                        |
| Smoking                                        | no                         |
| Alcohol consumption                            | yes                        |
|                                               | no                         |
| **2nd section: Oral hygiene status and the estimation of the rate of applying hygiene measures** |                            |
| 1. How many times during the day do you brush your teeth? | twice a day or more frequently | once a day or less frequently |
| 2. How do you clean your teeth?                | a toothbrush, fluoride toothpaste and dental floss | a toothbrush only |
| 3. How often do you change your toothbrush?    | once in 3 months           | once in 6 months or less frequently |
| 4. Do you use mouthwashes containing fluoride? | often                      | rarely or never |
| 5. Do you complain of bleeding on brushing or gingival bleeding? | rarely or never | at every brushing or almost at every brushing |
| 6. Do you suffer from tooth sensitivity?       | rarely or never            | often |
| 7. How often do you visit a dental clinic for a checkup? | once a year or more frequently | once every few years or in case of pain |
| 8. Do you have calculus regularly removed?     | once every few years, once a year or more frequently | rarely or never |
| 9. Are there any cavities in your teeth?       | no cavities at all / don't know / 1–2 cavities | 3 cavities or more |
| 10. Do you have teeth that are mobile?         | no / I don't know          | yes |
| 11. Did you suffer from any of the following before the epidemic? | bad smell / ulcerations / dry mouth / oral or dental pain / pain in jaw bones or joint | yes | no |
| 12. What were your oral hygiene measures while being infected with COVID-19? | increased | the same / decreased |
| **3rd section: COVID-19 symptoms**             |                            |
| 1. Was your PCR test result for COVID-19 positive? | yes | no |
| 2. Did you complain of fever?                  | yes                        |
| 3. Did you complain of cough?                  | yes                        |
| 4. Did you complain of a sore throat?          | yes                        |
| 5. Did you complain of malaise?                | yes                        |
| 6. Did you complain of a headache?             | yes                        |
| 7. Did you complain of diarrhea?               | yes                        |
| 8. Did you complain of the loss of smell sensation? | yes | no |
| 9. Did you complain of the loss of taste sensation? | yes | no |
| 10. Did you complain of muscle pain?           | yes                        |
| 11. Did you experience dyspnea or shortness of breath? | yes | no |
| 12. Did you need hospitalization?              | yes                        |
|                                               | no                         |
| **4th section: Oral manifestations**           |                            |
| 1. Did you complain of any oral manifestations while being infected with COVID-19? | yes | no |
| 2. If yes, which of the following did you complain of?    |                            |
| Halitosis (bad smell)                          | yes                        |
| Xerostomia (dry mouth)                         | yes                        |
| Ulcerations                                    | yes                        |
| Oral or dental pain                            | yes                        |
| Pain in jaw bones or joint                     | yes                        |

PCR – polymerase chain reaction.
Statistical analysis

Data was coded and entered using the statistical package IBM SPSS Statistics for Windows, v. 22.0 (IBM Corp., Armonk, USA). Categorical variables were summarized as frequency and percentage. Quantitative variables were summarized as mean (M) and standard deviation (SD). Comparisons between the groups, regarding the incidence of the studied parameters, were made using the \( \chi^2 \) test. A \( p \)-value <0.05 was considered statistically significant.

Results

Survey respondents

A total of 665 patients agreed to take part in the questionnaire. Ninety-two patients were excluded from the analysis: 9 were under 18 years old; 11 did not have a confirmed positive PCR test result; 3 had Sjögren's syndrome; 13 were hospitalized; 6 did not complete the questionnaire; 7 were smokers; 21 had chronic illnesses; 9 were not Egyptians; and 13 had poor oral hygiene. Therefore, the final analysis was performed on 573 patients. Overall, the respondents submitted the questionnaires from May 1, 2020 to July 1, 2020.

Demographic data

The mean age of patients was 36.19 ±9.11 years (range: 19–50 years). There were 408 females and 165 males. Regarding the educational level, patients were categorized into 3 levels: elementary education (\( n = 75 \)); bachelor's degree (\( n = 444 \)); and postgraduate education (\( n = 54 \)).

Analysis of COVID-19 symptoms

In this study, we mainly included patients with mild-to-moderate symptoms, without severe respiratory failure, who were not hospitalized. As reported in Fig. 1, the percentage of the respondents who suffered from fever was 66.0%, cough – 55.5%, a sore throat – 52.4%, malaise – 72.8%, a headache – 70%, diarrhea – 50.3%, the loss of smell – 61.8%, the loss of taste – 55.5%, muscle pain – 76.4%, and dyspnea – 51.8%.

Analysis of the oral manifestations of COVID-19 in the respondents

It was found that 71.7% of the patients presented with some oral manifestations, with variable incidence, at \( p < 0.001 \). Regarding oral or dental pain, it was expressed as 23.0%, pain in jaw bones or joint – 12.0%, halitosis – 10.5%, ulcerations – 20.4%, and xerostomia – 47.6%. Some respondents (28.3%) showed 2 or 3 manifestations simultaneously.

There were statistically significant differences (\( p < 0.001 \)) between the respondents’ answers regarding each symptom except for xerostomia, where \( p = 0.5 \) (Table 2).

The assessment of the incidence of oral manifestations in relation to the 4 investigated parameters (gender, age, the educational level, and the rate of the oral hygiene measures taken by the patient while being infected with COVID-19) was performed as follows:

– the assessment of the incidence of oral manifestations in relation to the patient’s gender – the statistical analysis identified a significantly increased number of ulcerations in male patients as compared to females (\( p = 0.02 \)); however, pain in jaw bones or joint was significantly increased in female patients as compared to males (\( p = 0.006 \)) (Fig. 2);

Fig. 1. Analysis of COVID-19 symptoms in mild-to-moderate cases
– the assessment of the incidence of oral manifestations in relation to the mean age of the respondents – the statistical analysis showed a non-significant difference in the mean age between the patients who complained of oral manifestations and those who did not ($p > 0.05$) (Fig. 3);
– the assessment of the incidence of oral manifestations in relation to the educational level of the respondents – the statistical analysis showed non-significant differences in the incidence of the oral symptoms associated with COVID-19 infection between the participants with a higher educational level and those with a lower level of education ($p > 0.05$) (Fig. 4);

Regarding the frequency of the oral hygiene measures taken while being infected with COVID-19, the patients were grouped according to their answers into 3 categories: 1 – those whose oral hygiene measures decreased while being infected (17.8%); 2 – those whose oral hygiene measures did not change (63.4%); and 3 – those whose oral hygiene measures increased while being infected (18.8%).
– the assessment of the incidence of oral manifestations in relation to the patient’s oral hygiene measures taken while being infected with COVID-19 – there was a statistically significant difference between the 3 groups of patients in the incidence of oral/dental pain ($p < 0.05$) and ulcerations ($p < 0.001$), with the highest percentage of oral pain and ulcerations observed in the patients with decreased hygiene measures, and the lowest percentage of oral pain and ulcerations in the patients with increased hygiene measures (Fig. 5).

### Table 2. Data regarding the respondents’ oral manifestations while being infected with COVID-19

| Oral manifestations | Answer | Number $n$ | Percentage [%] | $\chi^2$ | $p$-value |
|---------------------|--------|------------|----------------|---------|-----------|
| Occurrence of oral manifestations | yes | 411 | 71.7 | 6.00 | <0.001* |
| | no | 162 | 28.3 | | |
| Pain in jaw bones or joint | yes | 69 | 12.0 | 110.00 | <0.001* |
| | no | 504 | 88.0 | | |
| Halitosis | yes | 60 | 10.5 | 119.37 | <0.001* |
| | no | 513 | 89.5 | | |
| Ulcerations | yes | 117 | 20.4 | 66.85 | <0.001* |
| | no | 456 | 79.6 | | |
| Xerostomia | yes | 273 | 47.6 | 0.40 | 0.500 |
| | no | 300 | 52.4 | | |
| Oral or dental pain | yes | 132 | 23.0 | 55.50 | <0.001* |
| | no | 441 | 77.0 | | |
| Combined manifestations | yes | 162 | 28.3 | 36.00 | <0.001* |
| | no | 411 | 71.7 | | |

* statistically significant differences between the answers ($p < 0.001$).

![Fig. 2. Incidence of oral manifestations in relation to gender](image)

* statistically significant differences between males and females ($p < 0.05$).
Fig. 3. Incidence of oral manifestations in relation to the mean age of the patients

Fig. 4. Incidence of oral manifestations in relation to the educational level of the patients

Fig. 5. Incidence of oral manifestations in relation to the rate of the hygienic measures taken by the patients while being infected with COVID-19

* statistically significant differences between groups (p < 0.05 for dental/oral pain and p < 0.001 for ulcerations).
Discussion

Clinical evidence shows that the oral mucosa is a primary site of entry for SARS-CoV-2, and is considered possibly at high risk of susceptibility to the 2019 novel coronavirus (2019-nCoV) infection. However, there is still uncertainty whether the above-mentioned oral manifestations result from direct viral infection or from systemic health deterioration and impaired immune system.6 The aim of the present work was to investigate the oral manifestations which could be associated with mild-to-moderate cases of COVID-19 infection.

In the present work, patients experienced the general signs and symptoms of COVID-19 infection, which are fever, cough, a sore throat, malaise, a headache, diarrhea, the loss of smell, the loss of taste, muscle pain, and dyspnea. This is in accordance with several clinical studies, which reported these symptoms as the most prevalent ones in mild and moderate cases of COVID-19 infection.9 In addition, hospitalized patients were excluded to avoid the variable of different drug usage. Moreover, a relatively narrow age range of participants was chosen, excluding subjects aged >50 years, who are considered by WHO more prone to experience severe COVID-19 symptoms.1,3 In the current study, 47.6% of COVID-19 patients manifested xerostomia. This is in accordance with many cases, in which respiratory tract infections were reported as the main cause of xerostomia.10 In addition, a study involving 108 patients with confirmed COVID-19 in Wuhan reported that 46% of them complained of xerostomia.11 In another study, 32% of patients reported dry mouth as one of their symptoms; xerostomia appeared before the onset of other general COVID-19 symptoms.12

It has been stated that the target of SARS-CoV-2 are angiotensin-converting enzyme 2 (ACE2)-positive cells. Angiotensin-converting enzyme 2 is detected in the duct epithelium of the salivary glands. Therefore, the salivary glands are a possible target for COVID-19 infection.13 It is speculated that SARS-CoV-2 can enter the epithelial cells of the salivary gland duct, multiply in them and be discharged into saliva. A study by To et al. demonstrated that SARS-CoV-2 nucleic acid was found in the saliva samples of 91.7% of patients.14 It is hypothesized that SARS-CoV-2 infection results in pathological inflammatory lesions in the salivary glands, causing their lysis at the early stages of infection; then, the salivary glands may be later destroyed by the immunopathological reactions. These findings suggest that all other oral manifestations in COVID-19 patients may develop due to a decreased salivary flow. It has also been reported that with the infection progression, amylase may enter peripheral blood after acinar cell damage.13

Moreover, xerostomia reported in COVID-19 patients may be triggered by stress, as dry mouth is usually found in psychiatric patients. It is commonly correlated with nutritional deficiencies, anxiety, tension, and distress, which are often observed in the case of COVID-19 patients, who are stressed because of their fear of the disease, in addition to the stressful conditions of isolation.15,16

In this survey, 23% of COVID-19 patients experienced oral or dental pain. This pain could be referred from muscles, as it was reported in the current study that 76.4% of COVID-19 patients experienced myalgia. It has been proven that in case of muscle pain, neurons become sensitive and the stimulus is transmitted to central nerves via neurotransmission. Subsequently, pain which originates in muscles can be felt in the upper and lower jaws.17 Moreover, also headaches can be referred to the teeth; it was reported in the present study that 70% of COVID-19 patients suffered from headaches. In headaches, neuropeptides are released from trigeminal nerve endings and dilate blood vessels; then, the subsequent inflammation is proven to cause pain.17 In addition, it has been reported that orofacial or dental pain sensation can be enhanced by psychological distress or emotional disturbances, which is the case in nearly all COVID-19 patients.15,16

Furthermore, 20.4% of COVID-19 patients reported the appearance of ulcers in their oral cavities. This is in accordance with several cases, in which blisters and oral ulcers occurred during COVID-19 infection.9 It has been demonstrated that psychological upsets, such as anxiety and stress, contribute to the development and progression of oral lesions like recurrent aphthous ulcers, and this applies to COVID-19 patients.16 It has also been proven that psychological distress stimulates the immunoregulatory mechanism by elevating the leukocyte count at inflammatory sites.18 In addition, ACE2 is detected in the oral cavity and appears in high amounts in epithelial cells. It is elevated in the tongue, gingival and buccal mucosa. These findings demonstrate that the oral mucosa may be a target for COVID-19 infection.19

In the current study, 12% of patients complained of pain in jaw bones or joint. This is in agreement with several studies, where musculoskeletal pathologies, such as skeletal muscle, bone and joint disorders, were reported in COVID-19 patients and those with SARS-CoV-2 infection.20,21 It has been reported that in addition to potential direct viral infection, the cytokines and pro-inflammatory signaling molecules induced by the infection can impact skeletal muscles by reducing protein synthesis and stimulating muscle fiber proteolysis. The virus SARS-CoV-2 has been proven to infect type-II pneumocytes, which line the respiratory epithelium, and express ACE2 and transmembrane protease serine 2 (TMPRSS2).21 Angiotensin-converting enzyme 2 and TMPRSS2 are also expressed in numerous human skeletal muscle cells, several types of synovial cells, and different types of chondrocytes on articular surfaces and in the meniscus.22

Moreover, joint pain in COVID-19 patients is most probably caused by emotional distress rather than mechanical and occlusal aspects. Stressed people usually grind and clench their teeth. They eventually suffer from
muscle fatigue and spasm. Patients experiencing joint pain usually complain of psychological symptoms, such as irritation, fear, worry, uneasiness, tension, malnutrition, and insomnia, which are the symptoms commonly experienced by COVID-19 patients. In the present study, 10.5% of COVID-19 patients complained of halitosis. It has been reported that oral halitosis caused by respiratory tract infections may reach up to 10%. This could be due to the passage of sinus or nasal secretions into the oropharynx. The pungent gases produced by different respiratory pathogens are retained in the exhaled breath, stimulate olfactory receptors, and are released through the mouth or the nose, causing malodor. In addition, halitosis is also among the symptoms related to Helicobacter pylori infection, which is the major pathogenic cause of ulcerative alterations in the gastric mucosa. Moreover, gastroesophageal reflux disease is usually associated with halitosis.

Additionally, 28.3% of COVID-19 patients in the current study showed 2 or 3 of the above-mentioned oral manifestations concurrently. This could be due to the interaction of several mechanisms in the oral cavity, where ACE2 plays the major role due to its presence in various oral tissues.

The assessment of the incidence of oral manifestations in relation to the 4 investigated parameters showed that regarding gender, ulcerations were significantly more common in males than females. This is in accordance with a previous study, which showed the preponderance of ulcers among males. However, this is opposite to the findings of other investigation, which reported female prevalence. In the present study, it was probably hard to say what type of ulceration was present in the infected patients, since clinical examination was not applicable in the infected patients. However, we assumed that these ulcerations might be aphthous ulcers, as it has been reported that psychological stress plays an important role in the progression of recurrent aphthous ulcers, which is the case in nearly all COVID-19 patients, who experienced a very stressful situation. On the contrary, pain in jaw bones or joint was more common in females than males. This may be due to variations in estrogen levels between both sexes, as estrogen plays an essential role in bone health. Moreover, temporomandibular joint osteoarthritis is more prevalent in females, and can cause tenderness and pain in the joint region.

Regarding the mean age of the patients and their educational level, the statistical analysis showed non-significant differences in the incidence of oral symptoms in relation to these 2 measured parameters. It supports the hypothesis that these oral symptoms could result from direct viral infection and are not triggered by other variables.

As for the rate of the oral hygiene measures taken by the patients while being infected with COVID-19, it was reported that in the patients with decreased oral hygiene measures, ulcerations and dental/oral pain were significantly increased. This can be attributed to plaque and calculus accumulation around the teeth in case of poor oral hygiene, which will subsequently lead to the inflammation and ulceration of the gingiva, and eventually cause periodontitis, orofacial pain and tooth loss. This finding is confirmed by a study which investigated the complications of COVID-19 in patients with poor oral health. The authors proved that there was a link between elevated bacterial loads in the oral cavity and post-viral complications, and showed how improving oral hygiene measures could decrease the risk of COVID-19 complications.

In the current study, there were some limitations. Firstly, we were unable to include a control group, as the questionnaire was specifically designed for COVID-19 patients. To include a healthy population, it is required to design another version of the questionnaire, with different questions to suit healthy unaffected individuals, which could lead to contrasting answers, and thus inaccurate results.

Secondly, unfortunately, the number of female participants was greater than male participants. However, in our study, we did measure several parameters other than gender. Moreover, we were concerned with the presence of oral symptoms rather than the gender effect, as there is no exact proof in the literature that gender affects the presence or absence of oral manifestations associated with viral infections.

Finally, the clinical examination of patients was not applicable in the current work, as most of the dental and university clinics were closed at the time of the present investigation, treating only emergency cases.

Conclusions

It was proven that mild-to-moderate cases of COVID-19 infection were associated with oral manifestations, with variable incidence. The most frequent oral manifestation for the included participants was xerostomia, while the least expressed symptom was halitosis.

It was found that there was a significant increase in the expression of ulcerations in male patients. However, jaw bone/joint pain was significantly increased in female patients. Moreover, a statistically significant difference in the incidence of oral manifestations in relation to the oral hygiene measures taken by the patients while being infected with COVID-19 was noticed, with the highest percentage of ulcerations and oral pain observed in patients with decreased hygiene measures. Regarding the mean age of the participants and their educational level, there were non-significant differences between the patients who complained of oral manifestations and those who did not. Based on the above, the significance of dental examination of patients with communicable diseases should be highlighted and the role of a dentist as a member of a multidisciplinary team in assisting serious cases, such as COVID-19 patients, should be emphasized.
Recommendation

Further clinical studies are recommended to figure out whether oral manifestations in COVID-19 patients are due to direct viral infection or the emotional distress and stressful conditions experienced by the patients.

ORCID iDs

Nermeen AbuBakr https://orcid.org/0000-0003-2962-0070
Zeinab Amin Salem https://orcid.org/0000-0002-0126-3043
Amany Hany Mohamed Kamel https://orcid.org/0000-0002-3562-1099

References

1. World Health Organization. Novel Coronavirus (2019-nCoV). Situation Report – 22 (as of February 11, 2020). https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2. Accessed July 3, 2020.

2. World Health Organization. Coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032

3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585

4. Sinadinos A, Shellswell J. Oral ulceration and blistering in patients with COVID-19. Evid Based Dent. 2020;21(2):49. doi:10.1038/s41432-020-0100-z

5. Cojocaru DC, Georgescu A, Negru R. Oral manifestations in pulmonary diseases – too often a neglected problem. Int J Med Dent. 2015;19(2):117–123. https://www.semanticscholar.org/paper/ORAL-MANIFESTATIONS-IN-PULMONARY-DISEASES-%E2%80%93-TOO-A-Cojocaru-Georgescu-97e0b45e43ca83f7630922b9f6a798c495a-6be5e. Accessed July 8, 2020.

6. Kamel AHM, Basuoni A, Salem ZA, AbuBakr N. The impact of oral health status on COVID-19 severity, recovery period and C-reactive protein values. Br Dent J. 2021. doi:10.1038/s41415-021-2656-1

7. World Health Organization. Oral Health Surveys: Basic Methods, 5th ed. São Paulo, Brazil: School of Dentistry, University of São Paulo, Brazil:2013:Annex 7.

8. dos Santos JA, Costa Normando AG, Carvalho da Silva RL, et al. Oral mucosal lesions in a COVID-19 patient: New signs or second-ary manifestations? Int J Infect Dis. 2020;97:326–328. doi:10.1016/j. ijid.2020.06.012

9. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–2261. doi:10.1007/s00405-020-05965-1

10. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(6):641–649. doi:10.1016/S0030-4220(00)01184-7

11. Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. Cell Prolif. 2020;53(12):e12923. doi:10.1111/cpr.12923

12. Freini F, Meduri A, Gazia F, et al. Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol. 2020;41(5):102612. doi:10.1016/j.amjoto.2020.102612

13. Wang C, Wu H, Ding X, et al. Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis? Med Hypotheses. 2020;109:10789. doi:10.1016/j.mehy.2020.10789

14. To KKW, Tsang OTY, Yip CCY, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020;71(15):841–843. doi:10.1093/cid/ciaa149

15. Mehrotra V, Garg K, Raju MS, Sharma P, Singh R, Chauhan SK. Stress: As etiological agent for oral lesions – a research study. Rama Univ J Dent Sci. 2015;23(3):13–11. http://www.ramauniiversityjournal.com/pdf_oct/3-11.pdf. Accessed July 16, 2020.

16. Kaur D, Behl AB, Isher PPS. Oral manifestations of stress-related disorders in the general population of Ludhiana. J Indian Acad Oral Med Radiol. 2016;28(3):262–269. doi:10.4103/0972-1363.195671

17. Fukuda KI. Diagnosis and treatment of abnormal dental pain. J Dent Anesth Pain Med. 2016;16(1):1–8. doi:10.17225/jdpm.2016.16.11

18. Redwine L, Snow S, Mills P, Iwinn M. Acute psychological stress: Effects on chemotaxis and cellular adhesion molecule expression. Psychosom Med. 2003;65(4):598–603. doi:10.1097/01.psy.00007937768193.88

19. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:8. doi:10.1038/s41438-020-0074-x

20. Griffith JF. Musculoskeletal complications of severe acute respiratory syndrome. Semin Musculoskelet Radiol. 2011;15(5):554–560. doi:10.1055/s-0031-1293903

21. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020;92(7):726–730. doi:10.1002/jmv.25785

22. Isser LP, De Micheli AJ, Schönk MM, et al. Musculoskeletal consequences of COVID-19. J Bone Joint Surg Am. 2020;102(14):1197–1204. doi:10.2106/JBJS.20.00847

23. Bollen CML, Bekker T. Halitosis: The multidisciplinary approach. Int J Oral Sci. 2012;4(2):55–63. doi:10.1038/ijos.2012.39

24. Scully C, Felix DH. Oral medicine – update for the dental practi- tioner: Oral malodour. Br Dent J. 2005;198(9):498–500. doi:10.1038/ sj.bdj.4812806

25. Zürcher A, Filippi A. Findings, diagnoses and results of a halito-sis clinic over a seven year period. Schweiz Monatsschr Zahnmed. 2012;122(3):205–210. PMID:22418723

26. Kinberg S, Stein M, Zion N, Shaoul R. The gastrointestinal aspects of halitosis. Can J Gastroenterol. 2010;24(9):552–556. doi:10.1155/2010/639704

27. Okoh M, Ikechukwu O. Presentation of recurrent aphthous ulcer among patients in a tertiary hospital. Afr J Oral Health. 2019;8(2):8–12. doi:10.4314/ajoh.v8i2.185719

28. Patil S, Reddy SN, Maheshwari S, Khandelwal S, Shrutdi D, Doni B. Prevalence of recurrent aphthous ulcer in the Indian popula-tion. J Clin Exp Dent. 2014;6(1):36–40. doi:10.4317/jced.51227

29. Mani FM, Savisubramanian SS. A study of temporomandibular joint osteoarthritis using computed tomographic imaging. Biomed J. 2016;39(3):201–206. doi:10.1016/j.bj.2016.06.003

30. Meister TL, Brüggemann Y, Todt D, et al. Virucidal efficacy of differ-ent oral rinses against severe acute respiratory syndrome corona-virus 2. J Infect Dis. 2020;222(18):1289–1292. doi:10.1093/infdis/jiaa471